76 related articles for article (PubMed ID: 11889677)
1. Imatinib mesylate.
Davey MP
Clin J Oncol Nurs; 2002; 6(2):118-20. PubMed ID: 11889677
[No Abstract] [Full Text] [Related]
2. Imatinib mesylate.
Baker DE
Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
[TBL] [Abstract][Full Text] [Related]
3. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
[No Abstract] [Full Text] [Related]
4. Current status of imatinib as frontline therapy for chronic myeloid leukemia.
Marin D
Semin Hematol; 2010 Oct; 47(4):312-8. PubMed ID: 20875547
[TBL] [Abstract][Full Text] [Related]
5. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
Smith BD
J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
[No Abstract] [Full Text] [Related]
6. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
7. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Rosti G; Martinelli G; Baccarani M
Nat Med; 2007 Jan; 13(1):15; author reply 15-6. PubMed ID: 17206121
[No Abstract] [Full Text] [Related]
8. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Atallah E; Kantarjian H; Cortes J
Nat Med; 2007 Jan; 13(1):14; author reply 15-6. PubMed ID: 17206119
[No Abstract] [Full Text] [Related]
9. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Hatfield A; Owen S; Pilot PR
Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118
[No Abstract] [Full Text] [Related]
10. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Gambacorti-Passerini C; Tornaghi L; Franceschino A; Piazza R; Corneo G; Pogliani E
Nat Med; 2007 Jan; 13(1):13-4; author reply 15-6. PubMed ID: 17206117
[No Abstract] [Full Text] [Related]
11. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
12. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Griffin JM; Amand MS; Demetri GD
Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate and gray hair.
Etienne G; Cony-Makhoul P; Mahon FX
N Engl J Med; 2002 Aug; 347(6):446. PubMed ID: 12167692
[No Abstract] [Full Text] [Related]
14. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Kantarjian H; Sawyers C; Hochhaus A; Guilhot F; Schiffer C; Gambacorti-Passerini C; Niederwieser D; Resta D; Capdeville R; Zoellner U; Talpaz M; Druker B; Goldman J; O'Brien SG; Russell N; Fischer T; Ottmann O; Cony-Makhoul P; Facon T; Stone R; Miller C; Tallman M; Brown R; Schuster M; Loughran T; Gratwohl A; Mandelli F; Saglio G; Lazzarino M; Russo D; Baccarani M; Morra E;
N Engl J Med; 2002 Feb; 346(9):645-52. PubMed ID: 11870241
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.
Faivre S; Raymond E; Casiraghi O; Temam S; Berthaud P
J Clin Oncol; 2005 Sep; 23(25):6271-3; author reply 6273-4. PubMed ID: 16135502
[No Abstract] [Full Text] [Related]
16. [Management of chronic myeloid leukemia by imatinib].
Kizaki M
Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
[No Abstract] [Full Text] [Related]
17. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
19. Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.
Hong FS; Mitchell CA; Zantomio D
Pathology; 2010 Jan; 42(1):84-5. PubMed ID: 20025487
[No Abstract] [Full Text] [Related]
20. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
